Allogene Property Plant And Equipment Net vs Total Liab Analysis

ALLO Stock

USD 3.01 0.03 1.01%

Allogene Therapeutics financial indicator trend analysis is way more than just evaluating Allogene Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allogene Therapeutics is a good investment. Please check the relationship between Allogene Therapeutics Property Plant And Equipment Net and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

Property Plant And Equipment Net vs Total Liab

Property Plant And Equipment Net vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allogene Therapeutics Property Plant And Equipment Net account and Total Liab. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Allogene Therapeutics' Property Plant And Equipment Net and Total Liab is 0.94. Overlapping area represents the amount of variation of Property Plant And Equipment Net that can explain the historical movement of Total Liab in the same time period over historical financial statements of Allogene Therapeutics, assuming nothing else is changed. The correlation between historical values of Allogene Therapeutics' Property Plant And Equipment Net and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Net of Allogene Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Property Plant And Equipment Net i.e., Allogene Therapeutics' Property Plant And Equipment Net and Total Liab go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Allogene Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.As of the 17th of May 2024, Sales General And Administrative To Revenue is likely to grow to 792.18, while Selling General Administrative is likely to drop about 61.1 M.

	2021	2022	2023	2024 (projected)
Interest Income	1.7M	4.6M	14.8M	15.5M
Net Interest Income	1.7M	4.6M	14.8M	9.2M

Interest Income Net Interest Income

Allogene Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Net Invested Capital	Net Working Capital	Common Stock	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Retained Earnings Total Equity	Capital Surpluse	Capital Lease Obligations	Inventory	Other Current Assets	Property Plant And Equipment Gross
Other Current Liab		0.97	0.97	0.97	-0.8	0.95	0.23	0.93	0.98	0.97	0.97	0.94	0.77	-0.85	0.92	0.23	0.58	-0.31	0.04	0.37	-0.87	0.84	0.76	0.79	0.93	0.85
Total Current Liabilities	0.97		0.95	0.94	-0.71	0.87	0.19	0.86	0.94	0.95	0.96	0.87	0.67	-0.79	0.86	0.11	0.75	-0.27	0.2	0.24	-0.79	0.79	0.66	0.64	0.91	0.81
Total Stockholder Equity	0.97	0.95		0.99	-0.71	0.93	0.03	0.83	0.94	1.0	0.97	0.93	0.64	-0.74	0.82	0.15	0.57	-0.28	0.12	0.36	-0.78	0.74	0.63	0.71	0.89	0.73
Net Tangible Assets	0.97	0.94	0.99		-0.78	0.97	0.1	0.88	0.96	0.99	0.98	0.96	0.71	-0.79	0.85	0.26	0.55	-0.34	0.03	0.38	-0.81	0.8	0.7	0.74	0.88	0.78
Retained Earnings	-0.8	-0.71	-0.71	-0.78		-0.85	-0.51	-0.92	-0.88	-0.71	-0.73	-0.88	-0.96	0.97	-0.91	-0.73	-0.21	0.7	0.45	-0.46	0.95	-0.91	-0.95	-0.85	-0.71	-0.93
Common Stock Total Equity	0.95	0.87	0.93	0.97	-0.85		0.17	0.92	0.97	0.93	0.94	1.0	0.82	-0.85	0.88	0.41	0.39	-0.38	-0.2	0.36	-0.85	0.84	0.81	0.83	0.82	0.85
Common Stock Shares Outstanding	0.23	0.19	0.03	0.1	-0.51	0.17		0.53	0.29	0.03	0.05	0.18	0.61	-0.55	0.56	0.37	0.12	-0.29	-0.24	0.35	-0.57	0.61	0.6	0.48	0.36	0.59
Other Stockholder Equity	0.93	0.86	0.83	0.88	-0.92	0.92	0.53		0.96	0.83	0.84	0.92	0.93	-0.94	0.98	0.44	0.44	-0.41	-0.19	0.46	-0.96	0.97	0.92	0.88	0.87	0.96
Total Liab	0.98	0.94	0.94	0.96	-0.88	0.97	0.29	0.96		0.94	0.95	0.97	0.86	-0.91	0.94	0.36	0.49	-0.38	-0.12	0.35	-0.91	0.89	0.85	0.82	0.88	0.92
Net Invested Capital	0.97	0.95	1.0	0.99	-0.71	0.93	0.03	0.83	0.94		0.97	0.93	0.64	-0.74	0.82	0.15	0.57	-0.28	0.12	0.36	-0.78	0.74	0.63	0.71	0.89	0.73
Net Working Capital	0.97	0.96	0.97	0.98	-0.73	0.94	0.05	0.84	0.95	0.97		0.94	0.67	-0.79	0.81	0.23	0.6	-0.32	0.03	0.18	-0.75	0.73	0.66	0.7	0.9	0.76
Common Stock	0.94	0.87	0.93	0.96	-0.88	1.0	0.18	0.92	0.97	0.93	0.94		0.84	-0.87	0.88	0.46	0.37	-0.44	-0.23	0.37	-0.86	0.85	0.83	0.83	0.82	0.85
Short Long Term Debt Total	0.77	0.67	0.64	0.71	-0.96	0.82	0.61	0.93	0.86	0.64	0.67	0.84		-0.94	0.93	0.65	0.15	-0.52	-0.48	0.44	-0.94	0.93	1.0	0.87	0.67	0.96
Other Liab	-0.85	-0.79	-0.74	-0.79	0.97	-0.85	-0.55	-0.94	-0.91	-0.74	-0.79	-0.87	-0.94		-0.94	-0.65	-0.35	0.64	0.37	-0.31	0.94	-0.9	-0.94	-0.85	-0.81	-0.96
Property Plant And Equipment Net	0.92	0.86	0.82	0.85	-0.91	0.88	0.56	0.98	0.94	0.82	0.81	0.88	0.93	-0.94		0.41	0.41	-0.42	-0.16	0.5	-0.98	0.95	0.92	0.88	0.87	0.96
Net Debt	0.23	0.11	0.15	0.26	-0.73	0.41	0.37	0.44	0.36	0.15	0.23	0.46	0.65	-0.65	0.41		-0.32	-0.87	-0.86	0.18	-0.51	0.45	0.64	0.56	0.19	0.51
Other Assets	0.58	0.75	0.57	0.55	-0.21	0.39	0.12	0.44	0.49	0.57	0.6	0.37	0.15	-0.35	0.41	-0.32		0.03	0.65	-0.12	-0.31	0.42	0.14	0.06	0.63	0.4
Long Term Debt	-0.31	-0.27	-0.28	-0.34	0.7	-0.38	-0.29	-0.41	-0.38	-0.28	-0.32	-0.44	-0.52	0.64	-0.42	-0.87	0.03		0.53	-0.24	0.53	-0.42	-0.5	-0.45	-0.33	-0.46
Cash And Short Term Investments	0.04	0.2	0.12	0.03	0.45	-0.2	-0.24	-0.19	-0.12	0.12	0.03	-0.23	-0.48	0.37	-0.16	-0.86	0.65	0.53		-0.01	0.24	-0.17	-0.48	-0.43	0.1	-0.27
Net Receivables	0.37	0.24	0.36	0.38	-0.46	0.36	0.35	0.46	0.35	0.36	0.18	0.37	0.44	-0.31	0.5	0.18	-0.12	-0.24	-0.01		-0.59	0.54	0.42	0.54	0.3	0.35
Retained Earnings Total Equity	-0.87	-0.79	-0.78	-0.81	0.95	-0.85	-0.57	-0.96	-0.91	-0.78	-0.75	-0.86	-0.94	0.94	-0.98	-0.51	-0.31	0.53	0.24	-0.59		-0.95	-0.94	-0.89	-0.81	-0.94
Capital Surpluse	0.84	0.79	0.74	0.8	-0.91	0.84	0.61	0.97	0.89	0.74	0.73	0.85	0.93	-0.9	0.95	0.45	0.42	-0.42	-0.17	0.54	-0.95		0.92	0.79	0.75	0.96
Capital Lease Obligations	0.76	0.66	0.63	0.7	-0.95	0.81	0.6	0.92	0.85	0.63	0.66	0.83	1.0	-0.94	0.92	0.64	0.14	-0.5	-0.48	0.42	-0.94	0.92		0.87	0.66	0.96
Inventory	0.79	0.64	0.71	0.74	-0.85	0.83	0.48	0.88	0.82	0.71	0.7	0.83	0.87	-0.85	0.88	0.56	0.06	-0.45	-0.43	0.54	-0.89	0.79	0.87		0.79	0.8
Other Current Assets	0.93	0.91	0.89	0.88	-0.71	0.82	0.36	0.87	0.88	0.89	0.9	0.82	0.67	-0.81	0.87	0.19	0.63	-0.33	0.1	0.3	-0.81	0.75	0.66	0.79		0.76
Property Plant And Equipment Gross	0.85	0.81	0.73	0.78	-0.93	0.85	0.59	0.96	0.92	0.73	0.76	0.85	0.96	-0.96	0.96	0.51	0.4	-0.46	-0.27	0.35	-0.94	0.96	0.96	0.8	0.76

Click cells to compare fundamentals

Allogene Therapeutics Account Relationship Matchups

Allogene Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	717.8M	1.2B	1.0B	817.1M	642.8M	820.0M
Other Current Liab	23.8M	42.0M	34.3M	33.7M	24.3M	27.5M
Total Current Liabilities	33.1M	94.3M	48.2M	54.5M	37.1M	46.6M
Total Stockholder Equity	629.0M	1.1B	916.4M	665.9M	512.2M	708.1M
Net Tangible Assets	628.9M	1.1B	916.4M	665.9M	765.8M	732.1M
Retained Earnings	(396.1M)	(646.3M)	(903.3M)	(1.2B)	(1.6B)	(1.5B)
Accounts Payable	9.3M	10.4M	10.3M	13.9M	5.9M	9.7M
Cash	588.9M	1.0B	809.5M	576.5M	83.2M	79.0M
Non Current Assets Total	173.2M	382.7M	229.2M	288.3M	183.7M	245.6M
Non Currrent Assets Other	8.9M	14.6M	(322.1M)	32.7M	16.9M	17.7M
Common Stock Total Equity	121K	124K	140K	142K	163.3K	121.7K
Common Stock Shares Outstanding	101.1M	120.4M	135.8M	143.1M	156.9M	125.7M
Short Term Investments	355.4M	644.6M	284.0M	455.4M	365.5M	388.4M
Non Current Liabilities Total	55.7M	53.9M	74.1M	96.7M	93.5M	65.2M
Other Stockholder Equity	1.0B	1.7B	1.8B	1.9B	2.1B	1.4B
Total Liab	88.8M	148.2M	122.2M	151.2M	130.6M	111.8M
Net Invested Capital	629.0M	1.1B	916.4M	665.9M	512.2M	708.1M
Long Term Investments	63.2M	204.2M	352.2M	72.0M	3.6M	3.5M
Total Current Assets	544.6M	845.1M	809.5M	528.8M	459.1M	574.4M
Net Working Capital	511.5M	750.8M	423.1M	474.3M	422.0M	474.6M
Common Stock	124K	140K	142K	144K	169K	136.1K
Short Long Term Debt Total	51.3M	53.8M	69.9M	95.1M	95.1M	73.3M
Other Liab	4.4M	3.1M	4.1M	1.6M	1.4M	1.3M
Property Plant And Equipment Net	100.9M	160.1M	181.0M	196.4M	163.2M	154.6M
Net Debt	(537.5M)	(978.3M)	(739.6M)	(481.3M)	12.0M	12.6M
Other Assets	8.9M	263.9M	16.1M	16.9M	19.4M	18.4M
Cash And Short Term Investments	588.9M	1.0B	809.5M	576.5M	448.7M	556.9M
Net Receivables	2.4M	2.8M	6M	3.3M	3.8M	3.9M
Liabilities And Stockholders Equity	717.8M	1.2B	1.0B	817.1M	642.8M	695.7M
Capital Lease Obligations	51.3M	53.8M	69.9M	101.1M	95.1M	74.4M
Inventory	(60.7M)	(207.0M)	(20.0M)	(62.5M)	(71.8M)	(75.4M)
Other Current Assets	14.0M	17.2M	14.0M	11.5M	10.4M	13.3M
Property Plant And Equipment Gross	56.4M	160.1M	123.0M	233.3M	214.3M	145.9M
Accumulated Other Comprehensive Income	1.1M	268K	(2.6M)	(9.9M)	(955K)	(1.0M)
Capital Stock	124K	140K	142K	144K	169K	154K
Non Current Liabilities Other	4.4M	53.9M	74.1M	1.6M	5.2M	4.9M
Property Plant Equipment	100.9M	118.8M	123.0M	196.4M	225.9M	127.8M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:

How To Invest In Allogene

Details

Is Allogene Stock a good investment?

Details

What is Allogene Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Allogene Stock analysis

When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals

Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Revenue Per Share

0.001

Quarterly Revenue Growth

(0.27)

Return On Assets

(0.27)

Return On Equity

(0.55)

The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Allogene Property Plant And Equipment Net vs Total Liab Analysis

Property Plant And Equipment Net vs Total Liab

Property Plant And Equipment Net vs Total Liab Correlation Analysis

Correlation Coefficient

Property Plant And Equipment Net

Total Liab

Allogene Therapeutics fundamental ratios Correlations

Allogene Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Allogene Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Allogene Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Common Stock	+ 1.0	Common Stock Total Equity
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Net Invested Capital	+ 0.99	Net Tangible Assets
Total Liab	+ 0.98	Other Current Liab

Retained Earnings Total Equity	- 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.96	Other Liab
Retained Earnings Total Equity	- 0.96	Other Stockholder Equity
Short Long Term Debt Total	- 0.96	Retained Earnings
Capital Surpluse	- 0.95	Retained Earnings Total Equity
Capital Lease Obligations	- 0.95	Retained Earnings